Myocardial infarction associated with use of the synthetic cannabinoid K2.
about
Marijuana use and long-term mortality among survivors of acute myocardial infarctionAdverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and WithdrawalSynthetic cannabinoids 2015: An update for pediatricians in clinical practiceEmerging drugs of abuse: current perspectives on synthetic cannabinoidsGone to Pot - A Review of the Association between Cannabis and PsychosisSpice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoidsNPS: Medical Consequences Associated with Their IntakeThe role of illicit drug use in sudden death in the young.Designer drugs 2015: assessment and management.High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use.Adverse effects after the use of JWH-210 - a case series from the EU Spice II plus project.Emergence of new classes of recreational drugs-synthetic cannabinoids and cathinones.The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products.Cannabis use: signal of increasing risk of serious cardiovascular disorders.AKI associated with synthetic cannabinoids: a case series.The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse.A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment.High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with humSynthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.Novel psychoactive substances of interest for psychiatry.Synthetic cannabinoid use in a nationally representative sample of US high school seniors.Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry.Acute myocardial infarction, associated with the use of a synthetic adamantyl-cannabinoid: a case report.K2 and Spice use among a cohort of college students in southeast region of the USA.Acute intoxication caused by a synthetic cannabinoid in two adolescents.Cluster of Acute Toxicity from Ingestion of Synthetic Cannabinoid-Laced Brownies.Chest pain, troponin rise, and ST-elevation in an adolescent boy following the use of the synthetic cannabis product K2Modulating the endocannabinoid system in human health and disease--successes and failuresSynthetic Cannabinoid Use and Descriptive Norms among Collegiate Student-AthletesEmergency physicians' knowledge of cannabinoid designer drugsSpicing things up: synthetic cannabinoids.Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy.Elevated troponin levels in previously healthy children: value of diagnostic modalities and the importance of a drug screen.Neuropathology of substance use disorders.Nephrotoxic effects of designer drugs: synthetic is not better!Toxicology and management of novel psychoactive drugs.The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices.Downstream effects of endocannabinoid on blood cells: implications for health and disease.What is the Current Knowledge About the Cardiovascular Risk for Users of Cannabis-Based Products? A Systematic Review.
P2860
Q24629571-9F477E3E-1718-4B42-B9ED-BE88C62C2C19Q26748662-2AB30571-15E9-426E-BF41-73D17FFE8907Q26767016-24C77C26-6978-4572-ABA4-29C581B1BFA8Q26778885-7C9725C7-74D6-44B6-9AA8-483DF9ACD09EQ26865311-8744427F-BD5C-43C9-A2DE-9D1753CB6289Q27010555-961499C1-3792-4414-8ECE-6D50F3608236Q28276182-EF43E2E5-4938-4223-818D-26226392444BQ30239032-7BF71D6C-737E-46BB-A2AA-416B10F03023Q30300017-BE1CAADE-FE79-4B67-BBD3-4B8AB2E641ABQ33162567-78856859-7F85-48F3-9B1C-0B0AA965B590Q33166685-57D5F744-70EA-47D2-BEF3-21A2563EE391Q33906178-76FDF4E9-6C16-475B-904D-0E55035E18C1Q33908169-31D095A3-2818-4184-B022-C28D9F9D9984Q34297163-AE4CFD4F-978C-491D-97CA-60A056756C19Q34317945-953709E9-27F1-4087-8018-CBA6A2D422FCQ34336690-2FAA2D2B-292D-4914-ACB2-882E9FCF9EAAQ34501742-2F2CB812-F2BC-4C4C-9485-B3708AE23069Q34514221-BB59BF34-5FBF-41F0-9575-927CADD2C8FAQ34617484-036DB39C-3614-4F2A-99DE-A97EBF0249F7Q34667835-2822C86F-B2F2-4BD5-9883-B23D5EC5063CQ35181572-51BE5D05-AB35-492D-9E69-07DC82AD4424Q35254099-283BA982-8FC7-4265-BBE6-C06451D34081Q35895600-5261D52F-C747-4AF1-8BCF-9B7C4C730E99Q35920778-3A7683E0-D873-4EDF-8BF4-01ED9FE8C9A0Q36314660-8C6D656A-3340-4E14-B662-7B5EC02C3AD0Q36362726-C3C458E3-618F-49E9-A0D4-B7D9BEA0DBEEQ36662714-965A94C4-98A6-45A1-9DDA-2A99D87A187CQ36933683-D6E98191-2EDE-4BC9-8054-BF1248B902CCQ37095619-086D349E-9959-4C48-93C2-EDCEF6180659Q37213666-A002D887-FCBE-4DA5-A328-2CC7F296F8ABQ37237996-A7D46262-6325-42A3-ACCF-1F1767B3D487Q37575719-3719EFA6-2236-4E09-8548-ABE01022810CQ38086283-2233FCFC-39F9-452A-8D36-E9A1CA67ADADQ38167646-170974FE-2C79-4E43-83A0-3C33FF09AB33Q38198873-2A122273-2D51-4978-BB8A-FC09C5DECE40Q38254814-54CC6133-AC08-4ABF-9C9A-900F7FE9965CQ38317405-43DC317A-4CF9-4B51-9DF5-E08207A039ECQ38411456-A6246628-7782-4318-A04E-6300CB691314Q38468985-885EA7A3-D9D3-4725-BF0B-48AA2BBB9053Q38825532-A765B701-B9C9-4E2E-A3A7-612C5D6670BD
P2860
Myocardial infarction associated with use of the synthetic cannabinoid K2.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Myocardial infarction associated with use of the synthetic cannabinoid K2.
@ast
Myocardial infarction associated with use of the synthetic cannabinoid K2.
@en
Myocardial infarction associated with use of the synthetic cannabinoid K2.
@nl
type
label
Myocardial infarction associated with use of the synthetic cannabinoid K2.
@ast
Myocardial infarction associated with use of the synthetic cannabinoid K2.
@en
Myocardial infarction associated with use of the synthetic cannabinoid K2.
@nl
prefLabel
Myocardial infarction associated with use of the synthetic cannabinoid K2.
@ast
Myocardial infarction associated with use of the synthetic cannabinoid K2.
@en
Myocardial infarction associated with use of the synthetic cannabinoid K2.
@nl
P2093
P356
P1433
P1476
Myocardial infarction associated with use of the synthetic cannabinoid K2.
@en
P2093
Adebisi Obafemi
Arshid Mir
Colin Kane
P304
P356
10.1542/PEDS.2010-3823
P407
P577
2011-11-07T00:00:00Z